Australia Looks Into Funding Diagnostics For Targeted Drugs
This article was originally published in PharmAsia News
Australian authorities believe they may be able to save billions of dollars by backing development of diagnostic tests for targeted drugs. The government plans to explore the possibility of such a move, which could have an added advantage of preventing harmful side effects. The Australian Centre for Health Research estimated possible savings at more than U.S. $8.5 billion over the next five years. The study, conducted for the center by Deloitte Economics, named strokes, cholesterol, colorectal cancer and depression as among several diseases and drugs that would benefit from targeting. (Click here for more
You may also be interested in...
GlaxoSmithKline’s third quarter results included a 9% decline in sales in its vaccine business, but this was offset by tight cost controls and restructuring benefits; the company expects to continue investing in its pipeline and new product launches.
With many competitor programs on hold during the COVID crisis, L’Oreal dialed up its media investments and launched products over the summer that were postponed from the first quarter, resulting in a return to growth in the firm’s third quarter led by Professional Products and Active Cosmetics.
Just as the MDR and IVDR are being implemented, increasing regulatory divergence in Europe is a growing danger to patient safety throughout the EU. Erik Raadsheer, senior director of Align Technology, expressed concerns.